All In Biotech

Investigational drug · Phase 3

ASC30 A1

Also called: ASC30

Not approved by FDA. In 5 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Chronic Weight Management, Obesity, Overweight.

Phase 3

Last checked: Nov 19, 2026Latest source record: Oct 30, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations

Highest phase

Phase 3

Industry-sponsored trials

Phase 2 and 3 trials

5

2 still active

All registered trials

4

Any phase or sponsor naming "ASC30 A1"

First trial start

2024

Sep 16, 2024

Sponsors

Lead sponsors of its Phase 2 and 3 trials.

All registered trials by phase

Every ClinicalTrials.gov drug study naming "ASC30 A1", any sponsor or status.

Conditions studied

As listed on its trial records.

  • Chronic Weight Management
  • Obesity
  • Overweight
  • Type 2 Diabetes Mellitus
  • T2DM (Type 2 Diabetes Mellitus)

Approved drugs for the same conditions: Type 2 diabetes · Obesity and weight management · Cardiovascular and metabolic

Largest trials

Live from ClinicalTrials.gov: studies naming "ASC30 A1" as an intervention, largest first.

All trials

Newest research

PubMed records naming it or its code names, newest first.

All 1 on PubMed

Also in development for Chronic Weight Management

  • HRS-7535Phase 310 trials

    Shandong Suncadia Medicine Co., Ltd. · Type 2 Diabetes, Chronic Kidney Disease, Adults With Heart Failure, Mild Decrease in Ejection Fraction/Preserved Ejection Fraction, and Obesity

  • AleniglipronPhase 36 trials

    Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure Therapeutics · Obesity, Overweight, Chronic Weight Management

Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.